LivaNova (NASDAQ:LIVN - Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $3.05-3.15 for the period, compared to the consensus earnings per share estimate of $3.00. LivaNova also updated its FY 2024 guidance to 3.050-3.150 EPS.
LivaNova Stock Up 12.3 %
Shares of NASDAQ LIVN traded up $6.87 during trading on Wednesday, hitting $62.62. 2,460,064 shares of the company traded hands, compared to its average volume of 639,738. The business's fifty day moving average is $54.44 and its 200 day moving average is $50.85. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $63.21. The firm has a market capitalization of $3.39 billion, a price-to-earnings ratio of 195.69 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95.
LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The firm had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. During the same quarter in the prior year, the business earned $0.81 earnings per share. The business's quarterly revenue was up 12.8% compared to the same quarter last year. Equities research analysts predict that LivaNova will post 3.01 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
LIVN has been the topic of a number of analyst reports. Mizuho restated a buy rating and issued a $75.00 target price on shares of LivaNova in a report on Wednesday, March 27th. Barclays upped their target price on shares of LivaNova from $57.00 to $61.00 and gave the stock an equal weight rating in a report on Monday, February 26th. Needham & Company LLC restated a buy rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday. StockNews.com upgraded shares of LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Finally, Robert W. Baird increased their price objective on shares of LivaNova from $56.00 to $62.00 and gave the company a neutral rating in a research note on Thursday, February 22nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $64.40.
Check Out Our Latest Stock Analysis on LIVN
About LivaNova
(
Get Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Further Reading
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
